CSPI Comments to FDA Re: Risk-Based Enforcement Approach to Homeopathic Drugs
Homeopathic Drugs Could Benefit from Federal Oversight, Says CSPI
The group says it hopes the draft guidance signals enhanced federal attention on the homeopathic drug industry, now worth $3 billion dollars a year and growing quickly. It cites several examples of risky homeopathic products, including some linked to consumer injuries and deaths.
Topics